Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before the bell. Here’s what to look for.
Viatris beat analysts’ revenue expectations last quarter, reporting revenues of $3.52 billion, up 8.1% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and full-year revenue guidance meeting analysts’ expectations.
Is Viatris a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Viatris’s revenue to grow 2.6% year on year, a reversal from the 5.6% decrease it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Viatris has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Viatris’s peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 9.9%, beating analysts’ expectations by 3.6%, and Bristol-Myers Squibb reported revenues up 5.7%, topping estimates by 12.9%. Amneal traded down 4.1% following the results while Bristol-Myers Squibb was up 3.5%.
Read our full analysis of Amneal’s results here and Bristol-Myers Squibb’s results here.
Investors in the pharmaceuticals segment have had steady hands going into earnings, with share prices up 1.4% on average over the last month. Viatris is up 4.7% during the same time and is heading into earnings with an average analyst price target of $17.94 (compared to the current share price of $17.58).
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.